Order Article Reprints

Leem G, Jang S-I, Cho J-H, Jo JH, Lee HS, Chung MJ, Park JY, Bang S, Yoo D-K, Cheon H-C, et al. Safety and Efficacy of Allogeneic Natural Killer Cells in Combination with Pembrolizumab in Patients with Chemotherapy-Refractory Biliary Tract Cancer: A Multicenter Open-Label Phase 1/2a Trial. Cancers. 2022; 14(17):4229. https://doi.org/10.3390/cancers14174229

Leem, Galam, Sung-Ill Jang, Jae-Hee Cho, Jung Hyun Jo, Hee Seung Lee, Moon Jae Chung, Jeong Youp Park, Seungmin Bang, Da-Kyung Yoo, Hyo-Cheon Cheon, and et al. 2022. "Safety and Efficacy of Allogeneic Natural Killer Cells in Combination with Pembrolizumab in Patients with Chemotherapy-Refractory Biliary Tract Cancer: A Multicenter Open-Label Phase 1/2a Trial" Cancers 14, no. 17: 4229. https://doi.org/10.3390/cancers14174229

Leem, G., Jang, S.-I., Cho, J.-H., Jo, J. H., Lee, H. S., Chung, M. J., Park, J. Y., Bang, S., Yoo, D.-K., Cheon, H.-C., Kim, J.-E., Lim, K.-P., Jung, I.-H., Im, J.-M., Chung, Y.-Y., & Park, S. W. (2022). Safety and Efficacy of Allogeneic Natural Killer Cells in Combination with Pembrolizumab in Patients with Chemotherapy-Refractory Biliary Tract Cancer: A Multicenter Open-Label Phase 1/2a Trial. Cancers, 14(17), 4229. https://doi.org/10.3390/cancers14174229